You are here

P&T News

September 27

Regimen will target five tumor types and have seven indications
Endocrine Society publishes guideline evaluating technologies for treating diabetes
Combination did not improve progression-free survival for newly diagnosed patients
NIH-funded study seeks to explain the group’s disproportionate risk of the disease
Study includes nations that differ in economic development, income, and culture

September 26

Medication is indicated for the treatment of seven inflammatory diseases
It is the first biologic that targets interleukin-12 and interleukin-23 cytokines active in the disease
The potential blockbuster was granted breakthrough therapy status in 2014
Drug previously approved for cryopyrin-associated periodic syndromes and active systemic juvenile idiopathic arthritis
Studies also will address HIV prevention among at-risk groups

September 23

Another facet of national opioid epidemic?
Treatment improves progression-free survival versus standard chemotherapy
Scientists demystify popular MS drug
Subcutaneous nanoparticles may help control autoimmune disorders

September 22

New study comes amid price-hike furor
Sales staff downplayed drug’s addictive potential, court documents claim
Lantus gets the boot for diabetes
Participants could seek less-costly mix of patients, authors say

Pages